IMX 101

Drug Profile

IMX 101

Alternative Names: H. pylori vaccine - ImevaX; Helicobacter pylori vaccine - ImevaX; IMX101

Latest Information Update: 30 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImevaX
  • Class Bacterial vaccines; Helicobacter pylori eradication therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Helicobacter infections

Most Recent Events

  • 28 Oct 2014 ImevaX's Research programme: infectious disease vaccines is available for licensing as of 28 Oct 2014. http://www.imevax.com/
  • 28 Oct 2014 Preclinical trials in Helicobacter infections (Prevention) in Germany (Parenteral)
  • 28 Oct 2014 Preclinical trials in Helicobacter infections in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top